Governance
Chief Executive Officer
Before joining SGD Pharma as CEO in July 2022, Olivier Rousseau spent four years managing Verallia France as CEO and President of the bottle & jars glass packaging manufacturer. Prior to Verallia, Mr. Rousseau worked at The Goodyear Tire and Rubber Company for more than 20 years, where his roles included Chief Financial Officer of the EMEA region and leader of the Consumer business unit for the EMEA region, managing a portfolio with a turnover of €3 billion. Mr. Rousseau is focused on driving SGD Pharma’s mission to grow both organically and through acquisitions, providing customers with high quality, innovative products to meet their changing demands, while improving industrial performance across all plants
Chief Commercial Marketing & Innovation Officer
Carole Grassi Mircich has 15 years’ extensive experience in the packaging industry, firstly in the Beauty & Personal Care market and thereafter in the Pharmaceutical market. Carole joined SGD Pharma in 2017, initially as Marketing & Communication Director, then as a Chief Innovation & Development Officer and most recently in the role of Chief Commercial Marketing & Innovation Officer. Carole has introduced many strategic, market-driven and business development initiatives to increase the value of SGD Pharma for its customers, employees and shareholders. Prior to joining the pharmaceutical packaging industry at SGD Pharma, she spent 10 years at Rexam Packaging/Albéa Packaging in roles including Business Development/M&A and in strategic marketing and product management-innovation, after starting her career in finance.
Chief Operating Officer
William Ledger
Chief Operating Officer
General Manager BU West
Fabio Invernizzi
General Manager BU West
Fabio Invernizzi is General Manager of SGD Pharma’s West BU. In his previous role as Vice-President and EMEA Business Unit Head of Capsules and Health Ingredients at Lonza, Fabio supervised sales of €450 million per annum.
Chief Financial Officer
Philippe Pourquery
Chief Financial Officer
Chief Human Resources Officer
Pierre-Michel joined the company in 2016 as the Director of the Human Resources and internal communication.
Prior to joinging SGD Pharma, he spent 8 years with the Alstom group, first as VP HR/Organization Development & Learning then as HR Leader for various businesses (train services, power automation & control…). In 2015/2016, he managed the integration of his business unit within General Electric.
Before moving to HR, Pierre-Michel has been a Director at CapGemini Consulting, helping large companies in the telecom, life science, and manufacturing sectors manage their growth and transformation initiatives. He started his career in the automotive industry with BMW.
Pierre-Michel holds a business degree from ISC Paris and an MBA from HEC.
Group General Counsel
Caroline joined the company in December 2021 as Group General Counsel. Prior to that, Caroline has been Legal Director France and member of the executive committee of General Mills Yoplait for 5 years. She began her career working in various international law firms in M&A and corporate and commercial litigation practice over a period of 9 years and then joined Yoplait group as Legal Manager for International Transactions. She has a postgraduate degree in Business and Economic Law from the University of Paris I Panthéon-Sorbonne, she also obtained an LLM in Business and Company Law from the London School of Economics, and was admitted to the Paris Bar as French attorney.
General Manager China / Asia-Pacific
Frederic joined SGD Pharma in 1999. He held various positions in the sales team of North America (New York), Europe (Paris), Asia (Guangzhou) and India (Hyderabad-Vemula).
In 2013, he was part of the team managing the integration of Cogent Glass (now SGD Pharma India) as General Manager of the entity. Once the commercial and technical ramp-ups of SGD Pharma India were on the right track and with a strong team in place led by Akshay Singh, he returned to SGD Asia Pacific as General Manager.
Since 2017 he has participated with his teams in China to the turnaround of the commercial, industrial and profitability of SGD Pharma Asia Pacific, transforming it into the quality leader for molded Pharma and Beauty & Personal care in Asia.
General Manager India
Deepak Sood
General Manager India
Key facts
Business data
Turnover: 441 M€ (2023)
Global production capacity:
+ 8 Million vials per day
5 plants
7 furnaces
1 sorting facility
1 decoration workshop
Geographical areas: worldwide scope
90 agents & distributors
10 sales offices
Products’ categories & market applications:
Parenteral: molded injectable vials, tubular injectable vials, infusion bottles, ampoules
Oral: syrup bottles, tablet bottles, aerosol bottles, single dose bottle, droppers, bottles for antibiotics with filling mark
Baby bottles
Nasal bottles
Diagnostic bottles
Special needs: New designs & Innovation, plastic coating & printing, internal siliconization, ready-to-use, complete packs
Vials are carefully designed and manufactured with the highest integrity, ideally suited to a diverse range of application needs.
Social data
3063 employees
30% of women in top
management positions
245 person recruited in 2023
25,5 hours of training per employee per year
Environmental data
-18%
water consumption
-1,5%
GHG emissions on our European perimeter
+ 41%
of recycled waste
Milestones
Our CSR strategy
To minimize the impact of our business on the environment, we are prioritizing decarbonization. Our goal is to lead the pharmaceutical glass manufacturing industry with our decarbonization efforts, with the intention of reducing CO2 emissions by 35% by 2030 and by 65% by 2040. SGD Pharma is SBTI committed and currently working on the 1.5°C scenario decarbonation pathway validation including our scope 3 emissions.
2023Tubular and Corning partnership
SGD Pharma announced a joint venture with Corning to adopt the company’s Velocity® Vial coating technology and manufacture high-quality tubular vials at a new tube manufacturing facility in construction at SGD Pharma’s Vemula India production site.
This collaboration will help pharma companies respond to increasingly complex capacity and quality issues while meeting global demand for critical medicines. We broke ground on the $60M site in June 2023.
Olivier Rousseau appointed as new Chief Executive Officer
2022Inauguration of SGD Pharma India plant’s Unit V, fully dedicated to tubular glass packaging (capacity of 1 billion pieces by 2024).
The United Nations (UN) recognizes glass as an essential material and that this year, its contribution to society will be honored through the International Year of Glass 2022. SGD Pharma, as an official sponsor of the UN International Year of the Glass, will be spotlighting glass and its role in health and wellbeing.
2021PAI Partners (PAI), a leading European private equity firm, becomes SGD Pharma new shareholder.
Ecovadis Platinum medal - The group was awarded the Ecovadis Platinum medal, its Chinese plant and its subsidiary Embelia were both awarded the Silver medal.
2021Introduction of Type I molded glass enhanced offer: three distinct solutions - AXess, AXecure and AXpert - to help customers make an optimized choice, well-matched for specific requirements.
SGD Pharma starts a major Sucy-en-Brie plant development project, investing over 31M€ to rebuild one of the furnaces and modernize the site.
2020Introduction of Ensiemo, the new complete child-resistant packaging solution for CBD oils. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed its first complete packaging solution & services, Ensiemo: a wide range of dropper bottles and dropper, in clear or amber glass.
As part of its continuous improvement program, SGD Pharma optimized in 2020 the clear Type I glass composition of its best-in-class manufacturing plant at Saint-Quentin-Lamotte. This implementation provides a more robust process to improve the stability of the glass quality, improves the chemical resistance to reduce interaction with sensitive drug formulation and answers to stricter regulatory requirements.
2018Introduction of Sterinity. The Sterinity platform in partnership with Stevanato Group – a recognized RTU platform for injectable vials by the pharmaceutical industry - offers high quality pre-sterilized Type I molded glass to speed up aseptic filling processes and reduces time-to-market for high value parenteral drugs.
India plant's new Unit V is fully operational and 100% dedicated to our tubular product range.
2017Launch of Clareo. This new innovative range of vials offers a combination of homogeneous wall thickness and superior cosmetic quality, which is unique for the molded glass Type II market. Improved mechanical resistance, significant reduction in the breakage rate and improved inspectability are the main characteristics of Clareo.
SGD Pharma unveils its new identity. The new mission, vision and guiding principles support an ambitious growth strategy and a long-term vision for SGD Pharma.
2016JIC (China Jianyin Investment Ltd) becomes SGD Group new shareholder.
The new plant at Saint-Quentin-Lamotte produces its first glass vial on September 11th. December 21st marks the end of the pharmaceutical glass production at Mers-les-Bains after 57 years dedicated to this activity.
2014New manufacturing factory in Picardie at Saint-Quentin-Lamotte. SGD launched the newest, most modern plant in the world to manufacture molded glass pharmaceutical packaging. The construction lasted 13 months. The 13-hectare site benefits from a state-of-the art equipment (electrical and oxy-gaz furnaces) enabling an outage daily capacity of 1 million bottles and 20.000 tons per year.
The acquisition of an India-based manufacturer of Type I allows SGD Pharma to enter the tubular conversion market and to serve the fast-growing Indian pharmaceutical market.
2011Introduction of EasyLyo. EasyLyo provides a stronger packaging that is more resistant and suitable to extreme conditions encountered during the lyophilization process. EasyLyo is a range of Type I glass vials combining the strength of molded glass with superior cosmetic quality and weight reduction.
Oaktree Capital Management Ltd, an American investment firm, enters the Group’s capital on February 4th.
---Sorting-of-pharmaceutical-glass-packaging.jpg)
2008Acquisition of the Société de Services Verriers (SSV) company in France, dedicated to the sorting of pharmaceutical containers, which is a new activity for SGD Pharma.
Saint-Gobain Desjonquères becomes SGD Group. SGD Pharma is the first molded glass manufacturer to obtain the ISO 15378 certifications for all its pharmacy sites.
2005U-Save launch. The U-Save range is dedicated to nasal applications. The specific design of the U-Save molded vials provides 100% of product recovery for high value nasal spray drugs. Can be customised with plastic coating and/or decoration.
The acquisition of the Henri Desjonquères company by Saint-Gobain gives birth to Saint-Gobain Desjonquères, increasing its number of manufacturing sites worldwide: Kipfenberg (Germany), Santa Marina (Brazil), La Granja (Spain).
1958The furnace 4 at the Mers-les-Bains (France) factory is dedicated to the production of Type I molded glass.
Automation of the Mers-les-Bains (France) factory with IS machines.
1917Specialization of the factory in Sucy-en-Brie (France) in the production of pharmaceutical bottles in molded glass.
Henri Desjonquères founds Verrerie du Tréport, a glass manufacture factory in Mers-les-Bains (France), primarily aimed at the luxury perfumery market. The molded glass bottles are hand-blown.
Innovations
One of the keys to SGD Pharma’s leadership position in the glass industry has always been its drive to continually innovate.
Read more